Clinical Significance of Measuring Prostate- Specific Antigen
|
|
- Adrian Johnson
- 6 years ago
- Views:
Transcription
1 Clinical Significance of Measuring Prostate- Specific Antigen Borros M. Arneth, MS, MD (Institute of Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg University Mainz, Mainz, Germany) DOI: /LMEGGGLZ2EDWRXUK Abstract The incidence of prostate-specific antigen (PSA) monitoring has increased in recent years. However, interpretation of the results is often ambiguous and leads to uncertainty for both the patient and the treating physician. Advantages and disadvantages of measuring PSA and possibilities for improved interpretation using the variable PSA quotient are given. After reading this article, readers should be able to better interpret PSA values and assess the risk of prostate carcinoma using PSA quotient. In addition, errors associated with PSA and PSA quotient measurement are compared and discussed. Chemistry exam questions and corresponding answer form are located after this CE Update on page 492. The prostate gland is a chestnut-sized organ that lies directly under the bladder and encloses the upper section of the urethra. It is approximately 20 to 25 g in a young man and 30 g in an older man. During ejaculation, the prostate adds up to 40 g of a milky secretion to the ejaculate, in which prostate-specific antigen (PSA), a protein formed by the prostate gland, is present in high concentrations. 1-3 Prostatic secretions are slightly acidic with a ph around 6.4. The acidity serves to neutralize vaginal alkalinity and prolong the lifespan of spermatozoa. 4 PSA liquefies semen, promoting sperm motility, and serves to dissolve cervical mucus. PSA is present in low concentrations in the blood, but the concentration increases with prostate irritation, prostatic infection, and benign prostatic hyperplasia (BPH). PSA exists in the blood in two forms. Most PSA in blood is bound to serum proteins, some of which are inhibitors of the serine protease activity of PSA. Further, PSA is also present as free PSA. 5 Total PSA is the sum of both bound and free PSA; however, free PSA is measured only if the total PSA is increased. PSA is primarily a tissue-specific marker. From an elevated PSA measurement, it is difficult to differentiate between a benign and malignant transformation of the prostate gland. Distinguishing between the two is where free PSA is useful. Free PSA is more often formed from benign transformations while bound PSA tends to come from malign transformations. Both tests (free and total PSA) have high accuracy and repeatability. With increasing age, enlargement of the prostate gland is common and, in most cases, is benign. However, it often leads to unpleasant symptoms, such as problems with urination. The lifetime incidence of prostate carcinoma is 8% to 14% for Caucasian men 5 but prostate carcinoma will not be symptomatic in all of these men. Prostate carcinoma is rare in men under age 50 and the average age at diagnosis is 75 years. The risk is greater for men who have relatives with prostate carcinomas. 6 Only about 3% of the men with prostate carcinoma in Europe and in the United Glossary of Terms ACT-PSA BPH CV Complex PSA EDTA Free PSA PSA PSA EIA PSA ratio Total PSA Alpha-1-chymotrypsin prostate-specific antigen complex Benign prostatic hyperplasia Coefficient of variation Complexed portion of PSA Ethylenediamine tetraacetic acid Uncomplexed, free portion of PSA Prostate-specific antigen PSA enzyme immunoassay Quotient of free PSA to total PSA Free PSA + complexed PSA States die from this disease. A cure is more often possible if the tumor is recognized at an early stage; however, not all prostate carcinomas are aggressive. Some prostate carcinomas grow rapidly and metastasize. If not recognized at an early stage and treated appropriately, aggressive tumors often lead to death. Others grow slowly, remain asymptomatic, and do not extend to other organs. Cancerous prostate tissue usually releases more PSA and more complexed PSA into the blood than normal, healthy tissue does. Thus, an increased PSA may indicate the presence of prostate carcinoma. The higher the PSA concentration in blood, the more likely one is to find tumors that have extended beyond the prostate gland. 7 Today, asymptomatic and aggressive tumor forms can be differentiated most reliable by means of prostatic biopsy and subsequent histopathological investigation of the tissue. Until recently, PSA was thought to be produced only in the prostate; however, using very sensitive methods, PSA has now been found in low concentrations in many other tissues. The PSA molecule is very similar to kallikrein, which is androgen-dependent and produced in epithelial and glandular tissue. August 2009 Volume 40 Number 8 LABMEDICINE 487
2 Salient Points PSA is a glycoprotein produced predominantly, although not exclusively, by the prostate gland. PSA in blood may increase as a result of a variety of pathologic conditions of the prostate and may be a suitable marker for prostate carcinoma. For men over age 50, annual PSA screening is often recommended, although the value of this screening is disputed. Particularly at values below 10 µg/l (=10 ng/ml), the positive predictive value is rather poor for a carcinoma. Ultrasound, the rate of increase of PSA (PSA velocity), age-dependent reference values, and free PSA can significantly increase the predictive value of PSA measurement in cancer screening. 8 Blood from which PSA is attained should be drawn before digital rectal examination of the prostate gland The reference range for serum PSA is 0 4 µg/l and is dependent on the method used. PSA is usually elevated in the presence of prostate carcinoma; however, many benign conditions also result in PSA elevation. 6 The most important reason to measure PSA in blood is to screen for prostate carcinoma in men over age 50. In addition to screening, PSA is measured to evaluate the success of treatment and progression of disease when a known prostate carcinoma is present. However, an increased value does not always indicate carcinoma since studies have shown that about 70% of men with PSA values from 4 10 µg/l are free of prostate cancer. 13,14 Causes other than prostate carcinoma that can lead to elevated PSA values include: 1. Prostatic hyperplasia, one benign tumor, or several benign tumors of the prostate gland. Adenomatous hyperplasia is a common condition, occurring in more than half of all men over the age of ,16 2. Inflammation of the prostate gland (prostatitis), which is less common Prostate infarction and other causes, which are rare. 4. Manipulations to the prostate gland or ejaculation. 18 On the other hand, a normal value does not absolutely indicate that carcinoma is not present, since a considerable percentage of men with carcinoma of the prostate have serum PSA levels under 4 µg/l. 13 Also, overweight men have been shown to have lower PSA values. 19,20 In order to increase the predictive value of PSA measurements, the following 5 points have been found useful: 1. Digital rectal examination and ultrasonic investigation of the prostate gland 21 should be performed routinely. 2. Age-specific reference ranges (Table 1) should be considered. In younger men, elevated PSA and decreased free PSA fractions raise suspicion of prostate cancer even at lower values than are suspicious in older men. Table 1_Age-Specific Reference Ranges 3. PSA velocity should be determined. Prostate carcinoma usually produces more PSA and grows faster than does BPH. 22 Seventy percent of all men with prostate carcinoma show an increase in PSA of greater than 0.75 µg/l per year, whereas only 5% of all men without prostate carcinoma show a rise of this magnitude. In order to evaluate PSA velocity, several accurate measurements with comparable test methods and same sample type (ie, serum versus plasma) are necessary. 4. PSA density, free PSA, 23 and the free-to-total PSA quotient should be determined. Prostate carcinomas release much more PSA into the blood than benign prostate tumors. A small carcinoma can dramatically increase PSA levels, whereas the same increase can only be caused by a relatively large benign prostate tumor. PSA density is calculated by dividing the PSA concentration by the volume of the prostate gland as measured by ultrasound. High PSA values with a small prostate size (resulting in a high PSA density) raise suspicion for prostate carcinoma, whereas a low PSA density predicts benign tumors. One disadvantage of PSA density is that when a small carcinoma develops in a large benign tumor, the PSA density will be relatively low despite the presence of a carcinoma. PSA density is thus more useful when the prostate gland is small than when it is large. 7 Most PSA in the blood is bound to other proteins. 24 Normally, more than 23% of serum PSA is in its free form (free PSA). 25,26 Benign prostate tumors (prostatic hyperplasia, BPH) may be associated with elevated PSA, especially free PSA. With prostate carcinoma, however, the proportion of free PSA decreases. Why this occurs is unclear. One theory hypothesizes that prostate carcinoma produces not only PSA but also proteins to which the PSA is bound. As a result, the portion of free PSA decreases. The PSA quotient is computed by dividing the free PSA by the total PSA. The reference range for the PSA quotient is greater than 0.23 for PSA values of 4 to 10 µg/l and above 0.15 for PSA values below 4 µg/l. A lower quotient strongly suggests prostate carcinoma. A higher quotient suggests BPH. 5. Alpha-1-chymotrypsin-bound PSA (ACT-PSA), complexed PSA (cpsa), or both 24 should be found. As mentioned in the previous section, a majority of PSA in the blood is present in the bound form. Bound PSA, detectable in the blood, is often complexed with alpha-1-chymotrypsin. ACT-PSA may be measured instead of free and total PSA. The tests for cpsa measure different forms of bound PSA, among them ACT-PSA. These tests may replace traditional testing for free and total PSA. Some studies have shown improved discrimination between prostatic hyperplasia and prostate carcinoma through measuring cpsa. 24 Other studies, however, found no advantage in measuring cpsa or ACT-PSA over conventional measurement of free and total PSA. This issue is not resolved; however, new tests (cpsa, ACT-PSA) are likely to be at least as useful as traditional tests. % Free PSA Age Age Age >70 <10 49% 58% 65% % 34% 41% % 24% 30% >25 9% 12% 16% Probability in percent of a carcinoma depending on % free PSA and age (Roche Diagnostics Elecsys test 14 ). PSA, prostate-specific antigen. Tissue Biopsy For men with a PSA over 4.0 ng/ml, guidelines for the diagnosis of prostate carcinoma recommend that tissue samples should be obtained by needle biopsy and be examined by a pathologist. 27 At the present time, definitive diagnosis of prostate carcinomas can be made only through pathologic Downloaded 488 from LABMEDICINE Volume Number 8 August 2009 labmedicine.com
3 examination but prostate carcinoma cannot be definitively excluded by this method. For small tumors, the risk remains that the tumor was not contained within the biopsy specimen, and an unrecognized cancer remains. In addition, prostate biopsy is an invasive procedure, which introduces the risk of contamination of the biopsy site by tumor cells. Table 2_Interpretation of Prostate-Specific Antigen Values 32 PSA (ng/ml) % % >10 >49% Probability in Percent that a Carcinoma is Present Prostate-Specific Antigen Measurement Anti-PSA monoclonal antibodies are added to serum (or plasma) and incubated using standard methods and standard conditions. 28 Anti-PSA monoclonal antibodies bound to PSA are detected, and the probability that a carcinoma is present increases with increasing PSA. The following values are to be understood only as reference points as different studies have yielded different results (Table 2). The probability that a carcinoma is present rises as the proportion of free PSA decreases. The following values are reference points; different studies yield different results (Table 3). Specimens In principle, serum or plasma is suitable. If free PSA is desired, plasma (with heparin or EDTA anticoagulant) is recommended. Plasma should be separated by centrifugation within a short time of collection, preferably within 3 hours. The blood draw should take place prior to digital examination of the prostate gland. Table 3_Interpretation of Prostate-Specific Antigen Quotients 32 Probability in Percent that a Carcinoma is Present Free PSA (%) (PSA values between 4 and 10 µg/l, age 60 69) % % % >25 12% drawing blood can lead to increased PSA values. Elevated values decrease with a biological half-life of 2 to 3 days. Certain medications, including antiandrogens, inhibit progression of BPH and can lead to a decrease in PSA concentration. Further errors can result from the analytic measuring procedure. This error distribution is different for PSA and PSA quotient measurements as examined and presented in Table 5. Characteristics of the Roche Diagnostics Elecsys test are given in Table 4 (sensitivity and specificity) and Table 5 (imprecision of free and total PSA). Sample Storage for Measuring Total PSA and Stability of Free PSA A sample intended to measure total PSA, when stored at 20 C to 25 C, will see a 25% decrease in 1 week. It will remain stable for 5 days when stored at 4 C to 8 C. Free PSA is accurate for 1 day when a sample is stored at 4 C. Preanalytics When determining free PSA, plasma should be separated from cells within 3 hours of the blood being drawn. Interferences The following are examples of factors that will not interfere with the measurement of total PSA below specific levels (EIAII by Roche 28 ): No interference by hemoglobin up to 1 g/dl. No interference by bilirubin up to 60 mg/dl. No interference by triglycerides up to 2,000 mg/dl. Different medicines tested by the manufacturer did not influence results. Error Sources Palpation of the prostate gland, especially prostate massage, or surgical manipulation of the prostate gland before Gaussian Error Calculation/Analytic Measurement Error The coefficient of variation (CV) is the standard deviation divided by the mean value from a set of data. This is a close approximation of the mean relative error, which is the error divided by the measured value. In physics, it is common practice to calculate (or estimate) the measurement error of a product or quotient of 2 measured quantities, according to the Gaussian error propagation equation, which utilizes the Pythagorean Theorem: w/w = ( x/x) 2 + ( y/y) 2 Table 4_Characteristics of the Roche Diagnostics Elecsys Test Total PSA (µg/l) Free PSA/Total PSA Sensitivity Specificity % 63% % 82% < % 49% Table 5_Imprecision of Free and Total PSA (Roche Diagnostics Elecsys Test) Imprecision Lower Detection Limit Range Total PSA <3.7% ng/ml Free PSA <5.5% <0.01 ng/ml August 2009 Volume 40 Number 8 LABMEDICINE 489
4 Measurement of the day-to-day precision for free PSA yields a coefficient of variation (CV) of 1.71% for free PSA at 1.3 ng/ml, and a CV of 2.5% for free PSA at 1.6 ng/ml. For total PSA, a CV of 4.94% is found at 43.8 ng/ml and a CV of 4.67% is found at 44.5 ng/ml (data not shown). At free PSA values <5 ng/ml, the CV is approximately 2.5%. For total PSA, the CV is approximately 4.21% at the levels tested (see Table 6). The calculated error of the product of total PSA and free PSA is 4.89%. The calculated error of the free-psa-to total-psa quotient is 3.38%. Thus, the CV of the PSA quotient should be better than the error of total PSA alone (3.38%<4.21%). Practical CV Measurements Daily measurements of free PSA and total PSA, as well as calculated PSA quotients, are presented in Table 6. Free PSA has a CV of 2.5%, total PSA has a CV of 4.21%, and the free-psa-to-total-psa quotient has a CV of 2.94% (again, clearly less than the measurement error of the total PSA alone). Using controls of less than 5 ng/ml for free PSA and total PSA yields an even better CV for the free-psato-total-psa quotient than the theoretical value derived by Gaussian error calculations (see above 2.94% versus 3.38%). The errors for total PSA and for free PSA are presumably in the same direction, and consequently cancel out each other in the free-psa-to-total-psa quotient. The total PSA measurement error depends on the characteristics of the assay employed. By contrast, free-psa-to-total-psa quotients have Table 6_Daily Measurements of Free PSA and Total PSA in Control Subjects and Calculated Free-PSA-to-Total- PSA Quotient (Roche Diagnostics Elecsys Test) Total PSA <5 ng/ml or PSA = 5 ng/ml Free PSA Total PSA Free PSA/PSA , Mean SD CV % a measurement error considerably smaller than that of total PSA alone. The magnitude of this error is likely to be independent of the assay used. This observation holds true both for the theoretical derivation of the measurement error for the PSA quotient using the Gaussian error calculation and for the practical evaluation of the deviations from standardized control serum. The current study demonstrates that the PSA quotient should be given more attention in clinical practice. Compared with the measurement of total PSA alone, the PSA quotient is clearly associated with a much smaller measurement error (2.94% for the PSA quotient compared with 4.21% for total PSA alone), especially in the clinically relevant lower PSA range (total PSA <4.0 ng/ml). Further studies are warranted on the practical relevance of the PSA quotient. PSA Screening Pros and Cons Annual screening is recommended for men over 50, though some contend that PSA should not be measured in all men above 50. Some argue that untargeted screening does more harm than good, although no one denies that more prostate carcinomas are recognized with screening. 29 Opponents of untargeted PSA screening criticize those who favor it, claiming that surgical excision of prostate carcinoma is not always advantageous for the patient. 30 This assertion may not sound logical; however, it has not been proven that all prostate carcinomas should be treated. Finding an elevated PSA value may result in needless anxiety for the patient (and sometimes even for the doctor) and may result in unnecessary surgery with resultant impotence and urinary incompetence. The percentage of patients with asymptomatic prostate carcinoma who would develop clinically significant disease is unknown. Frankel and colleagues dispute the merits of broad screening because evidence from natural history is unhelpful since men are more likely to die with, rather than from, prostate cancer. 31 An emotional debate persists among experts. 32 Although we do not presume to resolve this controversy, we seek to elucidate the role that PSA may have in the diagnosis of this epidemiologically and economically important disease. Summary Prostate-specific antigen is a glycoprotein that is produced primarily by the prostate. It is a highly tissue-specific marker in serum, but it only has minimal disease specificity. To increase this specificity, various measures have been derived using the PSA concentration, such as PSA density, PSA velocity, and, in particular, PSA quotient. This quotient is calculated by dividing the concentration of free PSA by the total PSA concentration. In healthy patients, more than 23% of the total PSA content is free. In most patients with prostate carcinoma, less than 23% of the PSA exists in the free form. Although diagnostic improvements have been made through the use of PSA density, PSA velocity, and the PSA quotient, the diagnosis of prostate carcinoma by serum analysis is, nevertheless, accompanied by uncertainties. A definitive diagnosis of prostate carcinoma can be made only after tumor biopsy and histopathologic examination. LM Downloaded 490 from LABMEDICINE Volume Number 8 August 2009 labmedicine.com
5 1. Balk S, Ko Y, Bubley G. Biology of prostate-specific antigen. Am J Clin Oncol. 2003;28: American Society of Andrology. What is the prostate and what is its function? In: American Society of Andrology Handbook of Andrology. Ch. 8. Schaumburg, IL: ASH; Laux D, Custis M, Cutis S. Forensic Detection of Semen III. Detection of PSA Using Membrane Based Tests: Sensitivity Issues with Regards to the Presence of PSA in Other Body Fluids. Midwestern Association of Forensic Scientists; Lilja H. Biology of prostate-specific antigen. Urology. 2003;62: Catalona W, Partin A, Slawin K, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA. 1998;279: Thompson I, Pauler D, Goodman P, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millil. N Engl J Med. 2004;350: Lamerz R. PSA prostata spezifisches antigen. In: Thomas L, ed. Labor und Diagnose. Frankfurt am Main, Germany: TH-Books; 2000: Punglia R, Amico A, Catalona W, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349: Crawford E, Schutz M, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA. 1992;267: Chybowski F, Bergstralh E, Oesterling J. The effect of digital rectal examination on the serum prostate specific antigen concentration: Results of a randomized study. J Urol. 1992;148: Collins G, Martin P, Wynn-Davies A, et al. The effect of digital rectal examination on the serum prostate specific antigen concentration: Results of a randomized study. J Urol. 1997;157: Tarhan F, Orçun A, Küçükercan I, et al. Effect of prostatic massage on serum complexed prostate-specific antigen levels. Urology. 2005;66: Carter H. Prostate cancers in men with low PSA levels Must we find them? N Engl J Med. 2004;350: Mytrle J. Normal Levels of Prostate-Specific Antigen (PSA), Clinical Aspects of Prostate Cancer. Assessment of New Diagnostic and Management Procedures. Paper presented at: Prostate Cancer Working Group of the National Cancer Institute s Organ Systems Program. October 16 19, Prout s Neck, Me. New York: Elsevier; 1989: Carter H, Pearson J, Metter E, et al. Longitudinal evaluation of prostatespecific antigen levels in men with and without prostate disease. JAMA. 1992;267: Carter H. Assessing risk: Does this patient have prostate cancer? J Natl Cancer Inst. 2006;98: Nadler R, Humphrey P, Smith D, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154: Herschman J, Smith D, Catalona W. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997;50: Bañez L, Hamilton R, Partin A, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2004;350: Dreicer R. Why do obese men have lower PSA concentrations? Journal Watch (N Engl J Med). 2007;20: Catalona W, Richie J, Ahmann F, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151: D Amico A, Chen M, RoehL K, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351: Catalona W, Smith D, Ornstein D. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277: Christensson A, Björk T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150: Catalona W, Smith D, Wolfert R, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274: Chen Y, Luderer A, Thiel R, et al. Using proportions of free to total prostatespecific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology. 1996;47: Walsh P, DeWeese T, Eisenberger M. Localized prostate cancer. N Engl J Med. 2007;357: Roche Cobas product information. Elecsys Total-PSA and Free PSA Elecsys Gesamt-PSA und freies PSA. Roche Diagnostics. 2006; Catalona W, Smith D, Ratliff T, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324: Barry M. Prostate-specific antigen for early diagnosis of prostate cancer. N Engl J Med. 2001;344: Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet. 2003;361: Woolf S. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med. 1995;333: August 2009 Volume 40 Number 8 LABMEDICINE 491
Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationOverview. What is Cancer? Prostate Cancer 3/2/2014. Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014
Prostate Cancer Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014 Overview Start with the basics: Definition of cancer Most common cancers in men Prostate, lung, and colon cancers Cancer
More informationQuestions and Answers About the Prostate-Specific Antigen (PSA) Test
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Questions and Answers
More informationSERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE. A. AMAYO and W.
22 EAST AFRICAN MEDICAL JOURNAL January 2004 The East African Medical Journal Vol. 81 No. 1 January 2004 SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE.
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationProstate-Specific Antigen (PSA)
Prostate-Specific Antigen (PSA) The diagnosis of prostate cancer hinges on three primary factors: digital rectal exam, or DRE, (to be discussed) PSA testing, (discussed here) and ultrasound-guided biopsy.
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationIntroduction. Growths in the prostate can be benign (not cancer) or malignant (cancer).
This information was taken from urologyhealth.org. Feel free to explore their website to learn more. Another trusted website with good information is the national comprehensive cancer network (nccn.org).
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationProstate Cancer Testing. Don t be caught out
Prostate Cancer Testing Don t be caught out Prostate cancer testing What is Prostate Cancer? It is cancer of the prostate, a walnut-sized gland inside the body located in front of the urinary bladder in
More informationQuestions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test
Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test About Cancer Care Ontario s recommendations for prostate-specific antigen (PSA) screening 1. What does Cancer
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationProstate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics
Biomedical Engineering for Global Health Lecture Fourteen Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationAnnual Report on Prostate Diseases
An except from the HMS 2010 Annual Report on Prostate Diseases. To purchase the full report, visit www.health.harvard.edu/special_health_reports/prostate_disease Harvard Medical School 2010 Annual Report
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More informationEnzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum
Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum FOR RESEARCH USE ONLY Store at 2 to 8 C. PROPRIETARY AND COMMON NAMES f-psa Enzyme Immunoassay
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationPROSTATE CANCER CONTENT CREATED BY. Learn more at
PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationDetermination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer
Original Article DOI: 10.21276/APALM.1254 Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer Vineeth* G Nair and M. H. Shariff Department of Pathology, Yenepoya
More informationUtility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma
Disease Markers 19 (2003,2004) 287 292 287 IOS Press Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma V. Thakur a,, P.P. Singh b, M. Talwar c and U. Mukherjee
More informationADVICE TO PATIENTS REQUESTING PSA MEASUREMENT
Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want
More informationBLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER
BLADDER PROSTATE PENIS TESTICLES THE PROSTATE IS A SMALL, WALNUT-SIZED GLAND THAT IS PART OF THE MALE REPRODUCTIVE SYSTEM. IT RESTS BELOW THE BLADDER, IN FRONT OF THE RECTUM AND SURROUNDS PART OF THE URETHRA.
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationIntermethod Differences in Results for Total PSA, Free PSA, and Percentage of Free PSA
Clinical Chemistry / PSA and Free PSA Method Differences Intermethod Differences in Results for Total PSA, Free PSA, and Percentage of Free PSA Patricia R. Slev, PhD, Sonia L. La ulu, and William L. Roberts,
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationDoes normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
Original Article Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Sherif Azab 1, Ayman Osama 2, Mona Rafaat 3 1 Urology Department, Faculty
More informationDiagnosis and Classification of Prostate Cancer
Patient Information English 32 Diagnosis and Classification of Prostate Cancer The underlined terms are listed in the glossary. prostate biopsy is the only test that can confirm a prostate cancer diagnosis.
More informationThe Prostate Specific-Antigen (PSA):
The Prostate Specific-Antigen (PSA): Why it could not detect prostate cancer reliably in the past and How it became a sensitive and specific tumor marker Hans H. Glaettli, dipl. Phys. ETH 0. Summary PSA
More informationBAYESIAN JOINT LONGITUDINAL-DISCRETE TIME SURVIVAL MODELS: EVALUATING BIOPSY PROTOCOLS IN ACTIVE-SURVEILLANCE STUDIES
BAYESIAN JOINT LONGITUDINAL-DISCRETE TIME SURVIVAL MODELS: EVALUATING BIOPSY PROTOCOLS IN ACTIVE-SURVEILLANCE STUDIES Lurdes Y. T. Inoue, PhD Professor Department of Biostatistics University of Washington
More informationEvaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate
Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate Pages with reference to book, From 360 To 363 Farkhanda Ghafoor,Shahzad Khan,Bilquis Suleman,Aman Ullah Khan ( Departments of
More informationProstate Cancer Screening. A Decision Guide
Prostate Cancer Screening A Decision Guide This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Is screening right for you?
More informationUse of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate From Benign Prostatic Disease A Prospective Multicenter Clinical Trial William J. Catalona, MD; Alan W. Partin,
More informationProstate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer
Volume 1, Number 3 ISSN: 1932-9245 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and
More informationScreening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services
More informationThe prostate can be affected by three conditions that may cause problems for men as they get older.
The Prostate Gland The Prostate gland specific to males only, located in the pelvis between the bladder and rectum. It is about the shape and size of a walnut or satsuma and gets bigger as you get older.
More informationProstate CancerTest TM. Test Report
Test Report Patient Information Requisition Number Patient Name ID Number Date of Birth Gender M Patient Phone Number Patient E-mail Name of Lab Lab Phone Number Name of Physician Date of Collection Date
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationAge-Specific Reference Ranges for PSA in the Detection of Prostate Cancer
Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer Review Article [1] April 01, 1997 By Edward P. Deantoni, PhD [2] PSA is the best tumor marker yet discovered. Age-specific reference
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationDistribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer
Urological Oncology CHUN et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer Felix K.-H. Chun, Georg C.
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationMercy s Cancer Program 2014 Update
Mercy s Cancer Program 2014 Update Mercy Hospital & Medical Center is accredited Academic Comprehensive Cancer Program by the American College of Surgeon s Commission on Cancer. This study is directed
More informationWhat to Do with an Abnormal PSA Test. Feinberg School of Medicine, Chicago, Illinois, USA
The Oncologist Genitourinary Cancer What to Do with an Abnormal PSA Test STACY LOEB, a WILLIAM J. CATALONA b a Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; b The Northwestern
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS
The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E-mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk ADVICE TO
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationSome prostatic diseases
Some prostatic diseases Benign Prostatic Hyperplasia (Nodular Hyperplasia) Extremely common Present in a significant number of men by the age of 40 & its frequency rises progressively with age, reaching
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationPSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine
PSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine Abstract While PSA screening for prostate cancer remains a widely used tool
More informationTitle: The Use of Prostate-Specific Antigen in Prostate Cancer Diagnostics
Title: The Use of Prostate-Specific Antigen in Prostate Cancer Diagnostics Introduction: Prostate-specific antigen (PSA) is a serine protease produced in the prostate and secreted into ejaculate and blood.
More informationControversy Surrounds Question of Who Needs to be Treated for Prostate Cancer No One Size Fits All Diagnosis or Treatment
For Immediate Release Media Contact: Nancy Sergeant, Sergeant Marketing, 973-334-6666, nsergeant@sergeantmarketing.com Mary Appelmann, Sergeant Marketing, 973-263-6392, mappelmann@sergeantmarketing.com
More informationKEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 1 January 2014 PP.36-40 Serum Total Prostatic Specific Antigen and Prostatic Acid
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More information1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System. Now, we will explore two of the main problems associated
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationClinical Use of Tumor Markers Based on Outcome Analysis
CE UPDATE TUMOR MARKERS I Douglas C. Aziz, MD, PhD Does the test result change the way the clinician ABSTRACT Tumor markers are substances found in the thinks about the patient? serum or urine that can
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationThe Selenium and Vitamin E Prevention Trial
The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the
More informationTalking about Prostate Cancer
Talking about Prostate Cancer Talking about Prostate Cancer If I can avoid going to a doctor, I will but not when we re talking about prostate cancer. Why take chances with a condition that might be serious?
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationShared Decision Making in Breast and Prostate Cancer Screening. An Update and a Patient-Centered Approach. Sharon K. Hull, MD, MPH July, 2017
Shared Decision Making in Breast and Prostate Cancer Screening An Update and a Patient-Centered Approach Sharon K. Hull, MD, MPH July, 2017 Overview Epidemiology of Breast and Prostate Cancer Controversies
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationProstate Cancer Prevention with finasteride/proscar or dutasteride/avodart? Compiled by Charles (Chuck) Maack Prostate Cancer Advocate/Activist
Prostate Cancer Prevention with finasteride/proscar or dutasteride/avodart? Compiled by Charles (Chuck) Maack Prostate Cancer Advocate/Activist Disclaimer: Please recognize that I am not a Medical Doctor.
More informationIf you have aggressive cancer, you would want treatment in time for a cure.
Prostate cancer: PSA screening, biopsy, new technologies The treatment/cure should never be worse than the disease. If you have aggressive cancer, you would want treatment in time for a cure. What is PSA?
More informationTable 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups
Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationProstate Cancer. What Are the Risk Factors? Prostate cancer is the second leading cancer that causes death to men in the U.S.
Prostate cancer is the second leading cancer that causes death to men in the U.S. What Are the Risk Factors? Prostate cancer is unusual because it does not behave the same way in all men. Sometimes the
More informationIntroduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA
British Journal of Urology (1998), 81, 532 538 Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationProstate Cancer Screening (PDQ )
1 di 7 03/04/2017 12.22 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationBPH AND BEYOND. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD
BPH AND BEYOND B: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD Baylor Prostate Center, The Scott Department of Urology, Baylor College
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationRepeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Connolly, D., Black, A., Murray, L., Nambirajan, T., Keane, P. F., & Gavin, A. (2009). Repeating an abnormal
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationAge-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients
(2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *
More information4.5% 4.0% 3.5% 3.0% 2.5% 2.0% 1.5% 1.0% 0.5% 0.0% < >80 Current Age (Yrs)
Biomedical Engineering for Global Health Lecture Twelve Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United States:
More informationPatient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for
High Intensity Focused Ultrasound for Prostate Tissue Ablation Patient Information CAUTION: Federal law restricts this device to sell by or on the order of a physician CONTENT Introduction... 3 The prostate...
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More informationOBJECTIVE. significantly different classification rates of patients. These differences were even larger when using fixed %fpsa thresholds.
Original Article CLINICAL IMPACT OF DIFFERENT PSA ASSAYS STEPHAN et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits
More informationProstate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1
Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1 Review Article [1] August 01, 2002 By Alan W. Partin, MD, PhD [2], Gerald E. Hanks, MD [3], Eric A. Klein, MD [4], Judd
More informationSaving. Kidneys. Benign Prostate Disease
Saving Kidneys 9 Benign Prostate Disease This booklet will tell you more about the prostate gland. Its functions and benign hyperplasia have been defined in a simple way. Ways to prevent and treat this
More information